Literature DB >> 1372333

Anti-MAG IgM paraproteins from some patients with polyneuropathy associated with IgM paraproteinemia also react with sulfatide.

A A Ilyas1, S D Cook, M C Dalakas, F A Mithen.   

Abstract

Sera from five of 11 patients with neuropathy associated with IgM paraproteinemia (NAIgMPP) and reactivity against myelin-associated glycoprotein (MAG) also had elevated levels of IgM against sulfatide. Although three patients had anti-sulfatide IgM titers of less than or equal to 1:1000, two patients had titers of greater than or equal to 1:50,000. Absorption of patient serum with sulfatide revealed that anti-MAG IgM paraproteins in two patients with high titer anti-sulfatide IgM crossreacted with sulfatide. Our study is the first to show that some anti-MAG IgM paraproteins crossreact with sulfatide, a major acidic glycolipid of myelin. Moreover, some patients with NAIgMPP have polyclonal anti-sulfatide IgM in addition to anti-MAG IgM paraproteins. Therefore, sulfatide may be a target antigen in some patients with NAIgMPP.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372333     DOI: 10.1016/0165-5728(92)90158-h

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

Review 1.  Monoclonal IgM autoantibody reactivity in M-IgM peripheral neuropathy.

Authors:  C Caudie
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

Review 2.  Relationship between autoantibody specificities and peripheral nervous system involvements.

Authors:  M O Jauberteau-Marchan
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

3.  Polyneuropathies associated with high titre antisulphatide antibodies: characteristics of patients with and without serum monoclonal proteins.

Authors:  G Lopate; B J Parks; J M Goldstein; W C Yee; G M Friesenhahn; A Pestronk
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-06       Impact factor: 10.154

Review 4.  Antiglycolipid antibodies in peripheral neuropathy: fact or fiction?

Authors:  H J Willison
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

5.  Anti-sulphatide antibodies in peripheral neuropathy.

Authors:  L H van den Berg; C L Lankamp; A E de Jager; N C Notermans; P Sodaar; J Marrink; H J de Jong; P R Bär; J H Wokke
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-11       Impact factor: 10.154

6.  Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG.

Authors:  A A Ilyas; Y Gu; M C Dalakas; R H Quarles; S Bhatt
Journal:  J Neuroimmunol       Date:  2007-11-26       Impact factor: 3.478

7.  Immunotactoid-like endoneurial deposits in a patient with monoclonal gammopathy of undetermined significance and neuropathy.

Authors:  D F Moorhouse; R I Fox; H C Powell
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

8.  Lewis rats immunized with GM1 ganglioside do not develop peripheral neuropathy.

Authors:  Amjad A Ilyas; Zi-Wei Chen
Journal:  J Neuroimmunol       Date:  2007-06-07       Impact factor: 3.478

9.  Anti-MAG IgM: differences in antibody tests and correlation with clinical findings.

Authors:  Sabrina Matà; Stefano Ambrosini; Domenica Saccomanno; Tiziana Biagioli; Marinella Carpo; Aldo Amantini; Fabio Giannini; Alessandro Barilaro; Lucia Toscani; Monica Del Mastio; Giacomo Pietro Comi; Sandro Sorbi
Journal:  Neurol Sci       Date:  2019-10-25       Impact factor: 3.307

10.  Glycosphingolipid antigens in cultured bovine brain microvascular endothelial cells: sulfoglucuronosyl paragloboside as a target of monoclonal IgM in demyelinative neuropathy [corrected].

Authors:  T Kanda; H Yoshino; T Ariga; M Yamawaki; R K Yu
Journal:  J Cell Biol       Date:  1994-07       Impact factor: 10.539

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.